ArticleFEBS open bio2017
MiR-101 inhibits ovarian carcinogenesis by repressing the expression of brain-derived neurotrophic factor.
Article in FEBS open bio, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- BDNF and its signaling in cancer.Journal of cancer research and clinical oncology · 2023Review
- Extracellular vesicles derived from M2-polarized tumor-associated macrophages promote immune escape in ovarian cancer through NEAT1/miR-101-3p/ZEB1/PD-L1 axis.Cancer immunology, immunotherapy : CII · 2023Article
- Comparative Analysis of Tumor-Associated microRNAs and Tetraspanines from Exosomes of Plasma and Ascitic Fluids of Ovarian Cancer Patients.International journal of molecular sciences · 2022Article
- Extracellular vesicle contents as non-invasive biomarkers in ovarian malignancies.Molecular therapy oncolytics · 2022Review
- Exosome-Mediated Therapeutic Strategies for Management of Solid and Hematological Malignancies.Cells · 2022Review
- Nucleic acids and proteins carried by exosomes of different origins as potential biomarkers for gynecologic cancers.Molecular therapy oncolytics · 2022Review
- Current perspectives on clinical use of exosomes as novel biomarkers for cancer diagnosis.Frontiers in oncology · 2022Review
- Engineered EV-Mimetic Nanoparticles as Therapeutic Delivery Vehicles for High-Grade Serous Ovarian Cancer.Cancers · 2021Review
- Roles of miR-10a-5p and miR-103a-3p, Regulators of BDNF Expression in Follicular Fluid, in the Outcomes of IVF-ET.Frontiers in endocrinology · 2021Observational
- Neurotrophin Signaling in Medulloblastoma.Cancers · 2020Review
- Circulating Extracellular Vesicles in Gynecological Tumors: Realities and Challenges.Frontiers in oncology · 2020Review
- Low-Temperature Plasma Suppresses Proliferation and Induces Apoptosis in Lung Cancer Cells by Regulating the miR-203a/BIRC5 Axis.OncoTargets and therapy · 2020Article
- Circulating non-coding RNAs in recurrent and metastatic ovarian cancer.Cancer drug resistance (Alhambra, Calif.) · 2019Review
- LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression.Molecular cancer · 2018Article
- Advances of exosome in the development of ovarian cancer and its diagnostic and therapeutic prospect.OncoTargets and therapy · 2018Review
- Diagnostic and prognostic implications of serum miR-101 in osteosarcoma.Cancer biomarkers : section A of Disease markers · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer is one of the most lethal malignant gynecological tumors as a result of difficulties in early-stage detection and a lack of effective treatments for patients with advanced or recurrent cancer. In the present study, we aimed to explore whether some of the microRNA (miRNA) content of serum might be related to ovarian cancer, as well as the role of these miRNAs and their intercellular transport via exosomes in ovarian cancer. We first detected the expression of six candidate miRNAs in ovarian cancer tissues and adjacent nontumor ovarian samples from 36 patients and confirmed the altered expression of four miRNAs. The level of these six candidate miRNAs was also examined in exosomes from patient serum samples. Only the level of miR-101 was altered in both ovarian tissue samples and serum exosomes. After prediction using online bioinformatics tools and confirmation by dual-luciferase assay and immunoblotting, we identified that miR-101 can repress the expression of brain-derived neurotrophic factor by targeting its 3'-UTR. Using Transwell assays, we examined the effect of miR-101 on migration and invasion capacity of ovarian cancer cells. The results indicated that the reduction of miR-101 is mostly related to significant enhanced ovarian cancer cell migration. Thus, the results of the present study indicate that miR-101 content in serum exosomes has potential as a marker for diagnosis of ovarian cancer and that miR-101 mimics are potential therapeutic drugs for the treatment of ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.